Adairs (ASX:ADH) - Chairman, Brett Chenoweth
Chairman, Brett Chenoweth
Source: Adairs
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Adairs (ADH) has tabled unaudited group H1 FY22 financial results which show lockdowns and higher delivery costs have eaten away at earnings
  • Adairs says it expects underlying earnings before interest and tax (EBIT) to be between $32 million and $33 million for the six months ending December 31, down from $60.2 million the previous year
  • Adairs expects group sales to be nearly on par for its H1 FY21 result of $243 million, dipping slightly to $242 million
  • The most significant impact on Adairs’ total sales in the half was the government-mandated store closures with NSW and Victoria stores heavily impacted
  • Shares in Adairs are down 21.5 per cent on the market and are trading at $2.99

Adairs (ADH) has tabled unaudited group H1 FY22 financial results which show lockdowns and higher delivery costs have eaten away at earnings.

Adairs said it expects underlying earnings before interest and tax (EBIT) to be between $32 million and $33 million for the six months ending December 31, down from $60.2 million the previous year.

“Whilst gross margin will be below 1H FY21 as expected, it remains well ahead of 1H FY20 which was prior to the pandemic,” the company said in an announcement.

The company said gross margin has been impacted by global supply chain cost increases, higher delivery costs to online customers and additional promotional activity

Adairs expects group sales to be nearly on par for its H1 FY21 result of $243 million, dipping slightly to $242 million, but roughly $61.7 million above 1H FY20 results.

Of this $242 million, a $12.5 million contribution came from Focus on Furniture over a period of 26 days, which Adairs acquired in November. The company contributed $2.8 million to EBIT.

Group online sales, excluding Focus, were up 8.2 per cent to $97.6 million while Adairs and Mocka online sales were up 1.6 per cent and 22.8 per cent, respectively.

The most significant impact on Adairs’ total sales in the half was the government-mandated store closures with NSW and Victoria stores heavily impacted.

Adairs estimates that COVID-related shop closures affected its sales by $30-36 million and EBIT by $14-$18 million in the first half.

Stock flow into Australia and New Zealand from Asia remains inconsistent due to factory and shipping capacity disruptions.

“During the half, despite significant operational disruptions, we have made strides in progressing our strategic priorities by commissioning our new National Distribution Centre, upsizing selected stores, continuing to expand our range and adding to our omni-channel capabilities,” CEO and Managing Director Mark Ronan said.

“We also built our portfolio of vertical omni-channel retail brands by bringing forward the finalisation of the Mocka acquisition, and completing the acquisition of Focus on Furniture.”

Shares in Adairs were down 21.5 per cent on the market and were trading at $2.99 at 12:36 pm AEDT.

ADH by the numbers
More From The Market Online
The Market Online Video

ASX Market Close: Bourse finishes week on a high as Wisetech pummeled | November 22, 2024

The ASX200 closed up 0.85% at 8,393 points. Economists increasingly expect interest rates in Australia won’t…
The Market Online Video

HotCopper Highlights: Your most watched stocks for Week 47, 2024

In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing,…
Nuclear explosion mushroom cloud concept

Week 47 Wrap: HotCopper users’ most watched; Brent lifts on Putin’s scary letter; RFK dents CSL

Welcome to the end of another week. Let's start with what HotCopper users have been watching…
Dale Gillham's photo, and wording 'Words from Wealth Within's Chief Analyst Dale Gillham.

Dale Gillham’s weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in th…